Sanofi's pipeline bears fruit again with Cablivi approval

Within a day of announcing positive Phase III findings on its multiple myeloma candidate isatuximab, Sanofi (Euronext: SAN) has received approval from the US Food and Drug Administration (FDA) for another of its innovative assets.

The FDA has approved Cablivi (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults.

Cablivi is the first FDA-approved therapy specifically indicated for the treatment of aTTP and is the first drug to reach the US market from Sanofi’s newly formed rare blood disorders franchise.